Source: Annual Congress 2013 –Novel drugs for the treatment of asthma and COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Rinaldi, T. Denayer, S. Thiolloy, L. C. Perez Tosar, M. A. Buyse, P. De Decker, E. De Witte, P. Meerts, J. Baumeister, J. B. Holz (Zwijnaarde, Ghent, Belgium). ALX-0962, an anti-IgE Nanobody® with a dual mode of action. Eur Respir J 2013; 42: Suppl. 57, 1765

Member's Comments

No comment yet.

Related content which might interest you: Optimal technique for measuring the IgE blocked by omalizumab Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 QAW039, a slowly dissociating CRTh2 antagonist with potential for improved clinical efficacy Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Efficacy of omalizumab in Polish real-world patients Source: International Congress 2016 – Asthma management Year: 2016 Immune modulation of the T-cell response in asthma through Wnt10b Source: International Congress 2014 – Exploring molecular mechanisms of allergy and asthma in animal models Year: 2014 Evaluating omalizumab persistency of response after long-term therapy (XPORT) Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Asthma clusters in a real asthmatic population, treated in secondary medical care Source: International Congress 2014 – Asthma: clinical problems Year: 2014 QGE031 high affinity anti-IgE: Tolerability, safety, pharmacokinetics and pharmacodynamics in atopic subjects Source: Annual Congress 2013 –Treatment of asthma Year: 2013 The impact of sublingual allergen-specific therapy on asthma control and quality of life Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 The clinical and genetic factors for predicting the response to inhaled corticosteroids Source: International Congress 2014 – Biomarkers of asthma and clinical immunology Year: 2014 Investigating the role of BAFF in murine models of allergic asthma Source: International Congress 2014 – Paediatric asthma: markers and molecules Year: 2014 Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Safety profile and pharmacokinetics of SB010, an inhaled GATA-3-specific DNAzyme, in phase I clinical trials in healthy and asthmatic subjects Source: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013 Patterns of clinical use of omalizumab in Spain: A 5-year "real-life" study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 The results of the immunomorphological study of the placenta in women with asthma Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Safety, tolerability and pharmacokinetics of QAV680, an oral CRTh2 antagonist, in healthy subjects Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Fungal sensitization in patients with moderate and severe asthma Source: International Congress 2014 – Clinical allergy Year: 2014 Features of asthma treatment while pregnancy Source: International Congress 2014 – Asthma: clinical problems Year: 2014 Serum IL-10 and IL-17 are not related to the efficacy of allergen specific immunotherapy in asthma Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014 Chronic dosing effects of propranolol in asthma Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Characterization QAW039 and QAV680, two novel, potent and selective CRTh2 antagonists Source: International Congress 2014 – Allergy and asthma: novel findings based on human cell biology Year: 2014